Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501876-24-00

Acronym

BO43243

Enrollment

Registered

2023-04-11

Start date

2022-06-17

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026